Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Bringing Huntington’s Story to the Public: Q&A with Heather DeMyers

ByMike Hollan

January 30th 2026

Parental Control: Why Pharma’s Strongest Asset May Be Its Parent Brand

ByHugo Hensley

January 5th 2026

Actionable Insights at the Point of Care: A New Era in Provider Engagement

ByDoug Besch

December 10th 2025

Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?

ByThani Jambulingam, PhD

November 7th 2025

Deb Nevins is the Chief Marketing & Strategy Officer at POCN Group. POCN Group, an IQVIA business, is the life-sciences engagement division of POCN.

In Obesity Care, NPs and PAs Are the Influencers Marketers Can’t Ignore

ByDeb Nevins

November 7th 2025

RxClub Awards 2008: Powerful & Simple

Articles in this issue

Newsletter

Related Content

Bringing Huntington’s Story to the Public: Q&A with Heather DeMyers

Parental Control: Why Pharma’s Strongest Asset May Be Its Parent Brand

Actionable Insights at the Point of Care: A New Era in Provider Engagement

Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?

In Obesity Care, NPs and PAs Are the Influencers Marketers Can’t Ignore

Trending on PharmExec

Your Phase III Clinical Protocol Is Your Initial Product Launch

Pharmaceutical Executive Daily: Public Citizen Sues The Trump Administration Over Undisclosed Drug Price Agreements

AstraZeneca Enters $4.7 Billion Collaboration Agreement with CSPC Pharmaceuticals

Taking Advantage of ‘Hidden Gem’ Talent Hubs

What AI Trends Did You See at the 2026 JP Morgan Healthcare Conference?